London
· Delayed Price · Currency is GBP · Price in USD Vanda Pharmaceuticals Statistics
Total Valuation
LON:0LKB has a market cap or net worth of GBP 204.36 million. The enterprise value is -82.22 million.
| Market Cap | 204.36M |
| Enterprise Value | -82.22M |
Important Dates
The last earnings date was Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.03% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 52.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 5.45 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 5.03 |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.39 |
| Quick Ratio | 4.22 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.60 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -3.49% and return on invested capital (ROIC) is -4.60%.
| Return on Equity (ROE) | -3.49% |
| Return on Assets (ROA) | -3.90% |
| Return on Invested Capital (ROIC) | -4.60% |
| Return on Capital Employed (ROCE) | -7.31% |
| Revenue Per Employee | 431,449 |
| Profits Per Employee | -41,024 |
| Employee Count | 368 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 7.34 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.54% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +2.54% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 5.07 |
| Relative Strength Index (RSI) | 44.15 |
| Average Volume (20 Days) | 4,025 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.85 |
Income Statement
In the last 12 months, LON:0LKB had revenue of GBP 158.77 million and -15.10 million in losses. Loss per share was -0.26.
| Revenue | 158.77M |
| Gross Profit | 149.74M |
| Operating Income | -32.48M |
| Pretax Income | -18.31M |
| Net Income | -15.10M |
| EBITDA | -25.98M |
| EBIT | -32.48M |
| Loss Per Share | -0.26 |
Balance Sheet
The company has 299.25 million in cash and 9.87 million in debt, giving a net cash position of 289.38 million.
| Cash & Cash Equivalents | 299.25M |
| Total Debt | 9.87M |
| Net Cash | 289.38M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 430.17M |
| Book Value Per Share | 7.38 |
| Working Capital | 270.71M |
Cash Flow
In the last 12 months, operating cash flow was -12.59 million and capital expenditures -3.77 million, giving a free cash flow of -16.36 million.
| Operating Cash Flow | -12.59M |
| Capital Expenditures | -3.77M |
| Free Cash Flow | -16.36M |
| FCF Per Share | n/a |
Margins
Gross margin is 94.31%, with operating and profit margins of -20.46% and -9.51%.
| Gross Margin | 94.31% |
| Operating Margin | -20.46% |
| Pretax Margin | -11.53% |
| Profit Margin | -9.51% |
| EBITDA Margin | -16.36% |
| EBIT Margin | -20.46% |
| FCF Margin | n/a |
Dividends & Yields
LON:0LKB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.03% |
| Shareholder Yield | -1.03% |
| Earnings Yield | -7.39% |
| FCF Yield | -8.00% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0LKB has an Altman Z-Score of 1.78. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.78 |
| Piotroski F-Score | n/a |